Compare VAL & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VAL | DFTX |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2021 | 2020 |
| Metric | VAL | DFTX |
|---|---|---|
| Price | $97.92 | $37.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $69.00 | ★ $72.56 |
| AVG Volume (30 Days) | 755.4K | ★ 1.9M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $2,369,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.60 | N/A |
| P/E Ratio | $206.71 | ★ N/A |
| Revenue Growth | ★ 0.27 | N/A |
| 52 Week Low | $48.09 | $14.62 |
| 52 Week High | $114.12 | $49.70 |
| Indicator | VAL | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 54.23 |
| Support Level | $87.52 | $36.11 |
| Resistance Level | $104.05 | $38.04 |
| Average True Range (ATR) | 3.44 | 1.67 |
| MACD | 1.64 | 0.43 |
| Stochastic Oscillator | 90.02 | 87.21 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.